(Q57180634)

English

Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade

scientific article published on 08 October 2018

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30294755%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30294755%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

pancreatic cancer

1 reference

based on heuristic

inferred from title

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30294755%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

author name string

Jun Gong

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30294755%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Andrew Hendifar

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30294755%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Richard Tuli

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30294755%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Jeremy Chuang

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30294755%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

May Cho

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30294755%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Vincent Chung

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30294755%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Daneng Li

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30294755%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

language of work or name

0 references

publication date

8 October 2018

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30294755%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Clinical and translational medicine

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30294755%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30294755%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30294755%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

32

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30294755%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bystander effect of vinorelbine alters antitumor immune response.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

T cell exclusion, immune privilege, and the tumor microenvironment

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination cancer immunotherapy and new immunomodulatory targets

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination cancer immunotherapies tailored to the tumour microenvironment

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Current progress in immunotherapy for pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination immunotherapy: a road map.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined effect of anti-BAG3 and anti-PD-1 treatment on macrophage infiltrate, CD8(+) T cell number and tumour growth in pancreatic cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PD-1/PD-L1 and immunotherapy for pancreatic cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy in pancreatic ductal adenocarcinoma: an emerging entity?

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comprehensive Analysis of Hypermutation in Human Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of PD-L1 overexpression for pancreatic cancer: evidence from a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Emerging trends in the immunotherapy of pancreatic cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in advanced solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of resistance to immune checkpoint inhibitors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting cytokine therapy to the pancreatic tumor microenvironment using PD-L1 specific VHHs.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1/PD-L1 pathway.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy for pancreatic cancer: A long and hopeful journey

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Immune Revolution: A Case for Priming, Not Checkpoint

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30294755

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S40169-018-0210-9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30294755%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30294755%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30294755%20AND%20SRC:MED&resulttype=core&format=json

26 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57180634&oldid=2106590901"